PRO36 A US COST-MINIMIZATION MODEL COMPARING LIFETIME PER-PATIENT COSTS FOR RAVULIZUMAB AND ECULIZUMAB FOR THE TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME Y. Wang,K. Johnston,E. Popoff, K.J. Myren, A. Cheung, C. Faria, I. TomazosValue in Health（2020）引用 1|浏览43暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
